Relating to pharmaceutical benefits
HB5430 is a broad pharmacy-benefit reform bill affecting the Public Employees Insurance Agency (PEIA), Medicaid, and the regulation of pharmacy benefit managers (PBMs) in West Virginia. It requires PEIA contracts with PBMs to include detailed quarterly reporting on claims, reimbursements, fees, rebates, and spread pricing, and it authorizes PEIA to terminate contracts if required information is not provided. The bill also requires PEIA to solicit competitive bids for a pharmacy cost containment vendor by July 1, 2026, and directs Medicaid to create a one-year pilot program for a similar vendor focused on prescribing information, lowest-net-cost drug choices, and clinically appropriate reductions in polypharmacy.
The bill amends the Pharmacy Audit Integrity Act to add or clarify definitions and to impose new limits on PBM practices. Among other things, it prohibits PBMs from reimbursing West Virginia pharmacies below national average drug acquisition cost, or wholesale acquisition cost if NADAC is unavailable, plus a dispensing fee; bars PBMs from reimbursing pharmacies less than what the PBM pays itself or an affiliate for the same drug; restricts certain fees and revenue practices; and limits discriminatory treatment of 340B entities. It also requires PBMs to pass through rebates in a way that reduces member cost sharing and, for PEIA, directs 100% of rebates to the plan to reduce premiums. The bill further requires the Insurance Commissioner to conduct a recurring study of the cost to dispense outpatient prescription drugs in West Virginia.
The bill’s impact on state law is significant because it expands state oversight of PBMs, increases transparency requirements, and sets reimbursement floors and anti-affiliate rules that affect pharmacy contracts statewide. It also specifically applies several PBM protections to PEIA and makes PEIA subject to the Pharmacy Audit Integrity Act while carving out language to avoid conflict with Medicare. In addition, it creates new statutory duties for the Office of the Insurance Commissioner and establishes ongoing reporting and study obligations to the Legislature.
The overall sentiment around the bill appears strongly favorable and largely noncontroversial in the Legislature, as reflected by unanimous or near-unanimous votes in both chambers and on concurrence. The bill passed the House 92-0, the Senate 32-0, and concurrence in the House 94-0, indicating broad bipartisan support for PBM transparency, pharmacy reimbursement protections, and cost-containment efforts.
The main points of contention suggested by the text are not partisan but structural: how far the state can regulate PBM pricing and reporting without conflicting with federal Medicare rules, how much proprietary or nonproprietary data PBMs must disclose, and whether the new reimbursement floors and rebate pass-through requirements could affect plan costs or contracting flexibility. Another potential issue is the prohibition on PBM ownership or participation in group purchasing organizations for purposes of avoiding the act, which reflects concern about vertical integration and affiliate arrangements in the pharmacy supply chain.
HB5430 amends PEIA law, Medicaid law, and the Pharmacy Audit Integrity Act to impose new PBM transparency, reimbursement, rebate, and contracting requirements. It creates new reporting duties, competitive bidding requirements, a Medicaid pilot program, and a recurring state study of pharmacy dispensing costs, while also restricting PBM affiliate pricing, fee practices, and ownership structures. The bill directly affects PEIA, Medicaid, PBMs, pharmacies, pharmacists, 340B entities, and the Office of the Insurance Commissioner.
The legislative sentiment appears overwhelmingly supportive. The bill passed both chambers unanimously and was enacted effective from passage, suggesting broad agreement that PBM practices should be more transparent and that pharmacies and public health plans should receive stronger protections. The available record shows no recorded committee opposition or floor dissent.
The likely areas of contention are the scope of PBM regulation and the practical effects of the bill’s pricing rules. Stakeholders could disagree over mandatory disclosure of claims and rebate data, reimbursement floors tied to NADAC or wholesale acquisition cost, the requirement to pass through rebates to reduce premiums, and the limits on PBM affiliate and GPO arrangements. The bill also expressly avoids conflict with Medicare, indicating sensitivity to federal preemption and compliance issues, and the Medicaid pilot’s savings-guarantee structure may raise questions about implementation and vendor selection.